Radiation Therapy for Gynecological Cancer
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Gynecologic Oncology".
Deadline for manuscript submissions: closed (30 September 2024) | Viewed by 2782
Special Issue Editors
Interests: gynecologic cancer; gynecologic brachytherapy; late effects; survivorship
Special Issue Information
Dear Colleagues,
Radiation has been a mainstay in the definitive and adjuvant treatment of gynecologic cancers for decades. Over time, radiation treatment approaches for gynecologic cancers, treatment techniques, and technology have continually improved. Radiation treatment strategies that were previously based primarily on histological type, grade, and stage, are now being refined to incorporate clinical risk stratification, molecular/biomarker classification and treatment response; these risk-adapted approaches can inform escalation and de-escalation of treatment to improve outcomes. In addition, there have been advances in radiation techniques, including stereotactic ablative radiotherapy techniques and image-guided brachytherapy, that may further improve the toxicity profiles of radiation treatment.
Risk-adaption radiation approaches are exciting new opportunities to optimize the risk/benefit profile of treatment for gynecologic cancer. In this Special Issue of Current Oncology, we will present original research and review articles addressing the varied concepts of risk-adaption of radiation therapy in gynecologic cancer.
Dr. Ericka M. Wiebe
Dr. Iwa Kong
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- gynecologic cancer
- radiation therapy
- risk adapted
- molecular pathology
- biomarkers
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
